This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Strong Buy Stocks for December 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
5 Losing Stocks From 2019 to Rebound Next Year
by Maharathi Basu
The positive sentiment witnessed by Wall Street in 2019 might be prevalent in 2020 as well owing to multiple tailwinds.
Alnylam's Kidney Disease Drug Succeeds in Late Stage Study
by Zacks Equity Research
Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.
5 Beaten-Down Biotech Stocks Set to Rebound in 2020
by Kinjel Shah
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis
by Zacks Equity Research
Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.
The Zacks Analyst Blog Highlights: Baidu, Alkermes, Commvault Systems, Veoneer and Zuora
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Baidu, Alkermes, Commvault Systems, Veoneer and Zuora
Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote
by Zacks Equity Research
Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.
Biogen's Gosuranemab Fails in Phase II Brain Disorder Study
by Zacks Equity Research
Biogen's (BIIB) gosuranemab fails to meet primary endpoint in a phase II study evaluating gosuranemab (BIIB092) in patients with progressive supranuclear palsy, a degenerative brain disorder.
These 5 Loser Stocks of 2019 Could be Big Winners in 2020
by Anindya Barman
As the momentum in the equity markets is expected to stay on firm-footing in 2020, these five stocks that failed to stand out in 2019 have a chance to outperform next year.
Momenta Pharmaceuticals (MNTA) Catches Eye: Stock Jumps 7.1%
by Zacks Equity Research
Momenta Pharmaceuticals (MNTA) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Amgen's Osteoporosis Drug Evenity Gets Approval in Europe
by Zacks Equity Research
The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
Proteostasis Therapeutics (PTI) in Focus: Stock Moves 7.3% Higher
by Zacks Equity Research
Proteostasis Therapeutics (PTI) shares rose more than 7% in the last trading session, amid huge volumes.
TG Therapeutics' Shares Soar on Positive Early-Stage Data
by Zacks Equity Research
TG Therapeutics (TGTX) announces positive first clinical data from its once daily, oral, BTK inhibitor, TG-1701, as a single agent and as a triple therapy in combination.
Regeneron Reports Initial Data for Multiple Myeloma Drug
by Zacks Equity Research
Regeneron (REGN) reports initial data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma.
bluebird Reports Positive Top-Line Data on Myeloma Drug
by Zacks Equity Research
bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.
Sage Therapeutics' Depression Drug Fails in Study, Stock Down
by Zacks Equity Research
Sage Therapeutics' (SAGE) phase III study on pipeline candidate SAGE-217 for the treatment of major depressive disorder fails to meet the primary endpoint.
Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug
by Zacks Equity Research
Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.
Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon
by Zacks Equity Research
Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.
AstraZeneca Sells Schizophrenia Drug Rights in US and Canada
by Zacks Equity Research
AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.
Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 6.4% in Session
by Zacks Equity Research
Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Epizyme Announces FDA Committee Review of Tazemetostat NDA
by Zacks Equity Research
Epizyme (EPZM) announces that the FDA committee will review its NDA for lead candidate, tazemetostat, on Dec 18.
Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU
by Zacks Equity Research
The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.
Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1%
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Global Blood (GBT) in Focus: Stock Moves 5.2% Higher
by Zacks Equity Research
Global Blood (GBT) shares rose more than 5% in the last trading session, amid huge volumes.
BioDelivery's Belbuca Sales & Symproic Addition Encouraging
by Zacks Equity Research
BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.